Pembrolizumab, Cetuximab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HNSCC
Conditions
HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Trial Timeline
Mar 28, 2017 → Sep 11, 2025
NCT ID
NCT03082534About Pembrolizumab, Cetuximab
Pembrolizumab, Cetuximab is a phase 2 stage product being developed by Merck for HNSCC. The current trial status is completed. This product is registered under clinical trial identifier NCT03082534. Target conditions include HNSCC, Lip SCC, Oral Cavity Cancer.
What happened to similar drugs?
0 of 2 similar drugs in HNSCC were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03082534 | Phase 2 | Completed |
Competing Products
18 competing products in HNSCC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD2936 | AstraZeneca | Phase 2 | 42 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 32 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| eftilagimod alpha + pembrolizumab (KEYTRUDA®) | Merck | Phase 2 | 35 |
| Cetuximab/avelumab | Merck | Phase 2 | 42 |
| Ulevostinag + Pembrolizumab | Merck | Phase 2 | 35 |
| Motolimod + Nivolumab | Bristol Myers Squibb | Phase 1 | 21 |
| Nivolumab + Cisplatin + Cetuximab | Bristol Myers Squibb | Phase 1 | 29 |
| Nivolumab + Relatlimab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 42 |
| Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®) | Akeso | Phase 3 | 47 |
| FDC fianlimab+cemiplimab + Cemiplimab + Placebo | Regeneron Pharmaceuticals | Phase 2 | 42 |
| GTAEXS617 + SoC | Recursion Pharmaceuticals | Phase 1/2 | 33 |
| Ficerafusp alfa + Pembrolizumab | Bicara Therapeutics | Phase 2 | 36 |
| INBRX-106 + Pembrolizumab | Inhibrx Biosciences | Phase 2/3 | 39 |
| Tipifarnib + Alpelisib | Kura Oncology | Phase 1/2 | 26 |
| STRO-004 + Pembrolizumab | Sutro Biopharma | Phase 1 | 26 |
| DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2 | Phio Pharmaceuticals | Phase 1 | 23 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 22 |